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Background/aim: It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and
progression. miRNAs target a significant part of pathways as well as genes. This study aimed to compare the differential expression
profiles of miRNAs in prostate cancer and benign prostatic hyperplasia patients.
Materials and methods: Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n:
20) and benign prostatic hyperplasia (BPH) (n: 20) patients. Total RNA isolation was performed. As a result of the RNA concentration
and purity measurement, each patient group was pooled, and the miRNAs profiles comparison was performed with the Affymetrix
Microarray System.
Results: In tissue samples, 37 different expressed miRNAs were identified in PCa patients compared to BPH patients. In PBMCs samples,
27 different expressed miRNAs were identified in PCa patients compared to benign prostatic hyperplasia patients. As a result of the
comparison of tissue and PBMCs samples, it was determined that down regülated hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 were
common miRNAs. 3 (HIF1A, NHS,INSL4) targets identified for hsa-miR-494-3p, 2 (HIF1A, AVRP1A) for hsa-miR-3128, 3 (AVRP1A,
NHS, INSL4) for hsa-miR-8084.
Conclusion: Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A,
AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategies for prostate cancer. The present study may
represent the first in-depth analysis of PBMCs and tissue samples miRNA profiles.
Key words: Benign prostate hyperplasia, microarray, miRNA, prostate cancer

1. Introduction
PCa in men has been identified as the most diagnosed
cancer type when examining the frequency of cancer types
in terms of new cases and deaths in the World in 2018 [1].
Race differences, lifestyle, diet, age, family history, genetic
polymorphisms, and socioeconomic causes are among
the factors affecting the incidence of PCa. There are many
reasons why the frequency of PCa varies in the world.
Genetic and environmental factors constitute these two
main elements [2,3].
In the early diagnosis of PCa, prostate-specific antigen
(PSA) level [4], rectal examination, and transrectal
ultrasonography prostate biopsy methods are used quite
frequently [5,6]. Serum PSA is an important marker used
to monitor potential PCa patients. In addition, PSA value
appears to increase in prostate diseases such as BPH and

prostatitis. PSA is an organ-specific but not cancer-specific
test marker [6,7]. BPH, one of the prostate diseases, is a
nonmalignant but proliferative disease. The volume of the
prostate increases with age in normal men due to BPH.
BPH is not cancer, and it is not usually a serious threat
to health. If the prostate becomes enlarged, it can place
pressure on the bladder and the urethra. As a result,
difficulties in starting to void, frequent urination, and
the inability to empty the bladder can be seen. Global
incidence has in aged 50 and over more than 210 million
men. Their pathogenesis is largely unknown [8–10].
Since early-stage solid tumors have higher growth
potential than advanced-stage solid tumors, they undergo
apoptosis and necrosis less frequently. As a result of
this, early-stage solid tumors give restricted amounts of
extracellular molecules into the circulation. The available
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circulating extracellular biomarkers generally show a low
correctness for the early determination of solid tumors.
Also, the molecular changes of PBMCs are not reliant on
substantial tumor burden [11].
The rationale for using PBMCs as a biomarker for
solid malignant tumors is based on the mechanism by
which malignant growth causes characteristic changes in
the blood biochemical environment. These changes are
mostly related to the immune evasion mechanism of the
tumor itself and will affect the expression pattern of some
genes in blood cells [12]. Many miRNAs play a role in the
regulation of the expression level of these genes.
In the immune system, peripheral blood mononuclear
cells (PBMCs) act as the first line of defense against
malignancy, but so many studies have identified the
potential miRNA profiles for malignancies in a single
sample, such as tissue or serum/plasma instead of
PBMCs. However, in the same study; a) comparison of
tissue samples and PBMCs samples with microarray
system separately between PCa and BPH patient groups,
b) determination of miRNAs that overlap in miRNA
expression level in two different cell types, c) possible
targets and pathways of these miRNAs determined in PCa
patients research is almost nonexistent. The present study
may represent the first in-depth analysis of PBMCs and
tissue samples miRNA profiles.
2. Materials and methods
2.1. Patients and samples
From 40 patients who were followed up with clinical BPH
and PCa diagnosis, 4 different groups were formed: BPH
tissue (n: 20) and BPH PBMCs (n: 20), PCa tissue (n: 20),
and PCa PBMCs (n: 20). Prostate tissue and whole blood
samples were collected from Süleyman Demirel University
Hospital (Isparta, Turkey) between January 2021 and
August 2020.
The high dimensionality and complexity of the
correlation structure in microarray data, however, there
have been no sample size calculation methods accurately
reflecting the true correlation structure of real microarray
data [13]. Four to six samples per group have been
described as adequate in microarray analysis [14].
Biopsy samples were taken by urology specialists from
the area where the tumor tissue was located, under the
guidance of ultrasonography. The biopsy materials were
snap-frozen in liquid nitrogen after surgical resection
and then stored at −80 °C with the RNALater (Qiagen,
Germany) solution in cryotubes until RNA extraction.
Fifty micrograms of each sample tissue were homogenized
in Hibrigen HT buffer reagent with liquid nitrogen using
an ultrasonication (Bandelin Sonopuls HD 2070, Bandelin
Elec., Germany).

The patients who were diagnosed with PCa and BPH
randomly selected. None of the patients had received
any cancer therapy before the blood collection. It was
determined as a result of the examinations made by the
clinician that the patients did not have any malignancy
except for any prostate cancer clinically.
2.2. PBMCs separation from the whole blood sample
Peripheral venous blood was taken into the K2 EDTA
coated tubes (BD, Franklin Lakes, NJ). Within one hour of
blood draw, PBMCs were isolated as described by Huang
et al. [15]. PBMCs samples were stored at –80 °C until the
total RNA extraction.
2.3. Total RNA Extraction from tissues and PBMCs
Total RNA isolation was performed by Hibrigen Total
RNA extraction kit (MG-RNA-01-100) according to the
manufacturer’s protocol. A total of 250 µL PBMCs and 50
mg homogenization of tissue samples were used.
2.4. Quality control of the total RNA and pooled samples
RNA samples concentration and purity were determined
using NanoDropND-1000 spectrophotometer (NanoDrop
Technologies, Inc., Wilmington, DE). 260/280 nm ratio
was between 1.8 and 2.0. For four groups, the pooling
of RNA samples has performed at equal concentrations.
Final concentrations in the pools were verified again by
NanoDrop spectrophotometry.
2.5. Microarray labeling/washing/staining/scanning
procedure
The profiles of miRNAs was identified with the Affymetrix
Microarray System. GeneChip miRNA 4.0 (Affymetrix,
USA) commercial kit used in this system contains 30,434
mature miRNAs from 203 organisms and 2.025 premiRNA from humans, 2578 human mature miRNAs
Release 20.0 miRBase set [16].
The following operations were performed sequentially
with reference to the FlashTag Biotin HSR RNA Labeling
Kit procedure. Total RNA (200 ng) was labeled with
FlashTag Biotin HSR RNA Labeling Kit (Affymetrix,
USA). Then, array chips were hybridized with a
GeneChip Hybridization Control Kit (Affymetrix, USA).
Hybridization conditions were at 60 rpm, 48 °C for 16 h.
The chips arrays were washed and stained on a Fluidics
Station 450 with AGCC Fluidics Control Software.
Fluorescence was scanned with an Affymetrix GeneChip
3000-7G Scanner [16].
2.6. Statistical analysis
The following operations were performed sequentially with
reference to the TAC 4.0.2 user manual. Files of raw data to
be processed for analysis of miRNAs were created in *CEL
format with Affymetrix GeneChip Command Console
Software. Normalization of the data obtained after image
analysis was applied with the Transcriptome Analysis
Console (TAC) Software (version 4.0.2.15) provided by
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ThermoFisher/Affymetrix. The signal intensities of the
normalized sequences were compared with tests such as
t-test, ANOVA, and significance analysis of the microarray
after log2 translation. At least 2-fold differences (increase
or decrease) in microRNA expression at p < 0.05 were
assumed to be significant [16]. Comparison of PSA and
prostate value the two groups was conducted using the
Mann–Whitney U test.

2), 4+4 (n: 3), 4+5 (n: 1), 5+4 (n: 3), 5+5 (n: 1). All patients
clinical information given in Table 1.
3.2. Array results
As a result of array study the miRNAs identified using
TAC software are shown in Tables 2 and 3. The tables
show the up/downregulated miRNAs of PCa group
compared to BPH group in tissue and PBMCs samples.
Table 2 includes 13 miRNAs that upregulate in the tissues
and 24 miRNAs that downregulate. Table 3 includes 16
miRNAs that upregulate in the tissues and 11 miRNAs that
downregulate.
3.3. Prediction of the targets of the common prognostic
miRNAs
We predicted the targets of the three prognostic miRNAs
using the TAC software and miRTargetLink Human online
analysis tools. Each analysis tool identified unique targets
for the three miRNAs, but all two tools identified 3 (HIF1A,
NHS,INSL4) overlapping targets for hsa-miR-494-3p, 2
(HIF1A, AVRP1A) for hsa-miR-3128, 3 (AVRP1A, NHS,
INSL4) for hsa-miR-8084 (Figure). These results suggest
that overlapping miRNAs and their targets may play a role
in prostate cancer development and progression.

3. Results
3.1. Patient information
The age of patients ranges from 51 to 65 years. While the
mean age in PCa is 63 ± 2.9, it is 62.25 ± 4 in BPH. The
total PSA value mean was found to be 10.469 ± 11.6 ng/
mL in the PCa patient group, 6.3705 ± 8 ng/mL in the BPH
patient group, the prostate volume mean 67.75 ± 25 mL
in the PCa patient group and 98.5 ± 42.8 mL in the BPH
patient group. A statistical difference was found when the
PSA and prostate volumes of PCa and BPH patients were
compared (p < 0.05). PCa patients clinical information;
TNM stage T1a (n: 4), T1b (n: 5), T2a (n: 5), T2b (n: 1),
T2c (n: 2), T3b (n: 3), Gleason score 3+3 (n: 10), 3+4 (n:
Table 1. Clinical information of patients with PCa and BPH.
PCa

790

BPH

Age

PSA value ng/
mL

Prostate
volume

TNM
stage

Gleason
score

Age

PSA value ng/
mL

Prostate
volume

65

6.51

90

T1b

3+3

64

16

115

65

5.02

80

T1a

3+3

65

9.7

130

62

4.74

70

T1a

3+3

65

4.78

80

65

1.9

50

T1b

3+3

65

3.14

150

65

8

50

T1a

3+3

51

3.59

90

65

18.94

75

T1a

3+3

65

4.49

80

60

8

50

T2b

4+4

62

3.23

60

60

16.24

60

T3b

4+4

64

3.05

75

65

13.37

100

T1b

5+4

65

37.22

200

64

10.94

150

T3b

4+5

65

6.01

180

65

1.18

50

T1b

5+4

60

1.69

40

65

10.53

50

T2c

3+4

65

1.58

60

56

6.6

60

T2a

3+3

64

5.04

100

58

4.8

45

T2a

3+3

65

2.2

60

60

6.23

75

T2a

3+3

65

4.44

80

60

4.91

55

T2a

3+3

58

1.77

120

65

56.15

70

T2c

5+4

55

1.77

120

65

5.14

45

T3b

5+5

65

9.4

75

65

9.18

50

T2a

3+4

59

3.96

45

65

11

80

T1b

4+4

58

4.35

110
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Table 2. List of different expressed miRNAs of PCa group compared to BPH group in tissue samples.
Transcript
cluster ID

Transcript ID
(array design)

Accession
number

Fold change (linear)
(PCa vs. BPH)

Anova p-value
(PCa vs. BPH)*

Chromosome

20503803

hsa-miR-494-3p

MIMAT0002816

–5.22

0.0296

chr14

20515528

hsa-miR-3128

MIMAT0014991

–4.06

0.029

chr2

20500723

hsa-miR-27b-3p

MIMAT0000419

–3.57

0.0308

chr9

20500162

hsa-miR-30a-5p

MIMAT0000087

–3.46

0.0142

chr6

20529794

hsa-miR-8084

MIMAT0031011

–3.26

0.0181

chr8

20500144

hsa-miR-22-3p

MIMAT0000077

–3.02

0.0037

chr17

20500181

hsa-miR-99a-5p

MIMAT0000097

–2.87

0.0004

chr21

20517675

hsa-miR-378c

MIMAT0016847

–2.86

0.0077

chr10

20525633

hsa-miR-6780b-5p

MIMAT0027572

–2.8

0.0043

chr6

20518834

hsa-miR-4454

MIMAT0018976

–2.76

0.0123

chr4

20504396

hsa-miR-642a-3p

MIMAT0020924

–2.69

0.0498

chr19

20500183

hsa-miR-100-5p

MIMAT0000098

–2.67

0.0016

chr11

20500148

hsa-miR-24-3p

MIMAT0000080

–2.66

0.0387

chr19

20501312

hsa-miR-345-5p

MIMAT0000772

–2.54

0.02

chr14

20524036

hsa-miR-6126

MIMAT0024599

–2.47

0.0056

chr16

20518930

hsa-miR-4529-3p

MIMAT0019068

–2.38

0.013

chr18

20501287

hsa-miR-151a-3p

MIMAT0000757

–2.37

0.0164

chr8

20500444

hsa-miR-181a-5p

MIMAT0000256

–2.32

0.0388

chr1

20500746

hsa-miR-140-3p

MIMAT0004597

–2.29

0.0189

chr16

20519554

hsa-miR-4721

MIMAT0019835

–2.26

0.0142

chr16

20501243

hsa-miR-378a-3p

MIMAT0000732

–2.25

0.0029

chr5

20500484

hsa-miR-221-3p

MIMAT0000278

–2.15

0.0106

chrX

20500752

hsa-miR-143-3p

MIMAT0000435

–2.14

0.0267

chr5

20500159

hsa-miR-28-3p

MIMAT0004502

–2

0.0439

chr3

20535911

hsa-miR-1282

MI0006429

2.06

0.0035

chr15

20525657

hsa-miR-6848-5p

MIMAT0027596

2.12

0.0033

chr8

20519405

hsa-miR-4632-5p

MIMAT0022977

2.22

0.0049

chr1

20501237

hsa-miR-375

MIMAT0000728

2.23

0.0092

chr2

20501293

hsa-miR-331-3p

MIMAT0000760

2.23

0.0138

chr12

20505790

hsa-miR-885-3p

MIMAT0004948

2.24

0.0391

chr3

20519609

hsa-miR-4750-5p

MIMAT0019887

2.57

0.0016

chr19

20506896

hsa-miR-664a-5p

MIMAT0005948

2.62

0.0064

chr1

20521786

hsa-miR-5572

MIMAT0022260

2.65

0.001

chr15

20515637

hsa-miR-3195

MIMAT0015079

2.69

0.0031

chr20

20523007

hsa-miR-6075

MIMAT0023700

2.85

0.0287

chr5

20518625

hsa-miR-3937

MIMAT0018352

3.34

0.0141

chrX

20517902

hsa-miR-3651

MIMAT0018071

3.57

0.0115

chr9

*The statistical significant level was set at p-value < 0.05. Greater than two fold changes were analyzed for down/upregulated miRNAs.
In the table shown, a total of 37 miRNAs were found to be expressed differently.

791

SANCER et al. / Turk J Med Sci
Table 3. List of different expressed miRNAs of PCa group compared to BPH group in PBMCs samples.
Transcript
cluster ID

Transcript ID
(array design)

Accession
number

Fold change (linear)
(PCa vs. BPH)

Anova p-value
(PCa vs. BPH)*

Chromosome

20503803

hsa-miR-494-3p

MIMAT0002816

–3.45

0.0002

chr14

20515528

hsa-miR-3128

MIMAT0014991

–3.01

0.0054

chr2

20502446

hsa-miR-451a

MIMAT0001631

–2.65

0.0004

chr17

20500128

hsa-miR-16-5p

MIMAT0000069

–2.52

0.0105

chr13

20520204

hsa-miR-5004-5p

MIMAT0021027

–2.45

0.0025

chr6

20529794

hsa-miR-8084

MIMAT0031011

–2.37

0.0175

chr8

20500121

hsa-let-7e-5p

MIMAT0000066

–2.34

0.0019

chr19

20500721

hsa-miR-23b-3p

MIMAT0000418

–2.33

0.0005

chr9

20515646

hsa-miR-3201

MIMAT0015086

–2.31

0.0008

chr22

20504554

hsa-miR-668-5p

MIMAT0026636

–2.27

0.022

chr14

20504316

hsa-miR-548a-3p

MIMAT0003251

–2.01

0.003

chr6

20500782

hsa-miR-150-5p

MIMAT0000451

2.04

0.0193

chr19

20518788

hsa-miR-378f

MIMAT0018932

2.06

0.0148

chr1

20500771

hsa-miR-127-3p

MIMAT0000446

2.07

0.014

chr14

20509237

hsa-miR-1915-3p

MIMAT0007892

2.14

0.0005

chr10

20537261

hsa-mir-6089-1

MI0020366

2.15

0.0138

chrX

20537862

hsa-mir-6089-2

MI0023563

2.15

0.0138

chrY

20525699

hsa-miR-6869-5p

MIMAT0027638

2.18

0.0061

chr20

20525553

hsa-miR-6796-5p

MIMAT0027492

2.23

0.0069

chr19

20518880

hsa-miR-4486

MIMAT0019020

2.23

0.0008

chr11

20519573

hsa-miR-4730

MIMAT0019852

2.26

0.0058

chr17

20500761

hsa-miR-191-5p

MIMAT0000440

2.35

0.0006

chr3

20519493

hsa-miR-4687-3p

MIMAT0019775

2.37

0.0288

chr11

20514163

hsa-miR-2861

MIMAT0013802

2.45

0.0134

chr9

20518815

hsa-miR-4440

MIMAT0018958

2.48

0.0115

chr2

20517729

hsa-miR-4270

MIMAT0016900

2.88

0.0028

chr3

20525561

hsa-miR-6800-5p

MIMAT0027500

4.22

0.0004

chr19

*The statistical significant level was set at p-value < 0.05. Greater than two fold changes were analyzed for down/upregulated miRNAs.
In the table shown, a total of 27 miRNAs were found to be expressed differently.

4. Discussion
There are different methods such as tumor marker tests
and imaging systems used in the diagnosis of PCa. In our
study, we compared the results of the PSA test and prostate
volume measurement used in the diagnostic methods of
PCa and BPH patients. In the PCa group, the total PSA
was higher than the BPH group, while the prostate volume
was lower. We think the reason for the higher prostate
volume in the BPH group, may be caused by hormonal
changes that occur with increasing age.
However, we can explain the high level of total PSA in
PCa patients despite the low prostate volume that with the
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expression that PSA release per unit volume is higher in
the circulation in previous studies [17,18].
Although there are different methods such as tumor
marker tests and imaging systems used in the diagnosis
of PCa, understanding the molecular biology of cancer
is very significant in the early diagnosis and accurate
treatment of PCa.
miRNAs are used as a guide in the regulation of
gene expression in many types of cancers, diagnosis,
prognosis, and treatment alternatives [19]. Although
plasma/serum miRNA research studies are a promising
area for tumor markers for clinical applications, they
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Figure. In PBMCs and tissue samples common miRNAs and their predicted targets.

lack sufficient sensitivity and specificity to improve
early cancer detection [15]. PBMCs act as the first line
of defense against malignancy in the immune system.
In the case of dysfunctions, cancer immunogenicity or
immune evasion may occur. Therefore, molecular profiles
of PCMCs can provide new biomarkers for the early
detection of malignancies. Importantly, molecular changes
occurring in PBMCs are not dependent on tumor burden
as in extracellular biomarkers [11]. We think that after the
detection of biomarkers in tissues and PBMCs samples, the
comparison of similarities between them is very important
in the diagnosis/treatment of PCa and its differentiation
from BPH.
Some recent researches have revealed that hsa-miR494-3p, hsa-miR-3128, hsa-miR-8084 is involved in some
human diseases, such as prostate cancer, colon cancer,
breast cancer [20–22].
Previous studies have shown that hsa-miR-494-3p is
closely associated with different types of cancer and has
an increased expression level. It has been shown that this
increase affects signaling pathway PI3K/AKT and its main
target is PTEN [23–25]. On the other side, many studies
including this one published by Li et al. [26] found that
downregulation of microRNA-494 via loss of SMAD4
increases FOXM1 and β-catenin signaling in pancreatic
ductal adenocarcinoma cells.
Overexpression of LINC01410 induced N-cadherin
and vimentin expression while inhibiting E-cadherin
expression in osteosarcoma cells. Overexpression of
LINC01410 suppressed miR-3128 expression in MG63 cells. These data indicated that LINC01410 acted as

an oncogene [27]. Zhao et al. [28] found that LncRNA
LOXL1-AS1 was higher expressed in nonsmall cell lung
cancer tissues and promoted cancer progression by
regulating miR-3128/RHOXF2.
Although not many studies on miR-8084 in the
literature, Chong et al. [29] show that miR-8084 is the
most significantly downexpressed in recurrent epithelial
ovarian cancer.
In the present study, we found that the expression level
of hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 was
significantly downregulated in prostate cancer tissues and
PBMCs. These miRNAs predicted targets were HIF1ANHS-INSL4, AVRP1A-HIF1A, AVRP1A-NHS-INSL4,
respectively.
Tran et al. [30] found that hypoxia/HIF1a signaling
pathways independently promote prostate cancer
progression. Ivell et al. [31] expressed that nothing is
known about roles for INSL4 in male reproduction and
closely linked to the DMRT1 gene. INSL4 is not able to
interact with RXFP1 and RXFP2 receptors. INSL4 is only
known to be expressed in the human placenta, and is not
detectable in any tissue of the male reproductive tract.
AVPR1A is expressed on various cell lines such as
vascular smooth muscle, cardiomyocytes, hippocampus,
kidney, bone, liver, and breast and nonsmall cell lung
cancer. AVPR1A acts as receptor for arginine vasopressin.
This receptor mediates cell contraction, proliferation, and
glycogenolysis. Also, many available datasets from human
castrate-resistant prostate cancer specimens show that
AVPR1A gene copy number amplification [32]. AVPR1A
inhibition had benefit for end stage bone-metastatic CRPC.
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Recent reports have defined to influence and tolerability
of AVPR1A antagonism in autism spectrum disorder.
Also, supports the use of again AVPR1A antagonists for
advanced prostate cancer [33].
NHS protein is an actin regulatory protein that relevant
role in cell morphology by maintaining the integrity of the
circumferential actin ring and controlling lamellipodia
formation [34,35].
hsa-miR-494-3p, hsa-miR-3128, and hsa-miR-8084
downregulated miRNAs in tissues and PBMCs may cause
prostate cancer with changes in many points such as the
regulations of the cell cycle, signal transduction, and cell
communication. Also, it is mentioned in many studies that
the predicted targets HIF1A, AVRP1A, NHS, INSL4 have
a very important role in the progression of prostate cancer.
Our findings in our study are not only effective miRNAs
in prostate cancer but also related to other malignancies.
Our aim is to reveal the effect of these miRNAs in prostate
cancer.
In our study, miRNA expression levels are independent
of the disease stage. It was tried to determine the relation
of miRNAs with prostate cancer, not with metastasis. In
our future studies, it is aimed to correlate the expression
levels of these miRNAs with the progression of prostate
cancer by looking at the relationship between TNM and
Gleason scoring. Decreased levels of hsa-miR-494-3p, hsa-

miR-3128, hsa-miR-8084 and therefore likely to increase
levels of targets HIF1A, AVRP1A, NHS, INSL4 may be
novel biomarker candidates for early-stage diagnosis and
treatment of prostate cancer.
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